Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population
Targeting Wnt/-Catenin Pathway for Developing Therapies for Hair Loss
Quality control Your batch is inspected, labeled and sealed against the COA
In a similar way, when gut tissue becomes inflamed, KPV is preferentially taken up into that inflamed tissue to help shut down the inflammatory response
Product Attributes CAS # : 1034043-18-3 Molecular Formula : C10H11N2+ (free base), C10H11IN2 (iodide salt), C10H11ClN2 (chloride salt) Sequence (AA) : N/A (small molecule) Molecular Weight : 215.26 g/mol PubChem CID : 950107 (free base), 66522933 (iodide salt) Half-Life : 3.8-6.9 hours Synonyms : 5-Amino-1-methylquinolinium-1-ium, NNMT Inhibitor 5A1MQ, NNMTi, Amino-1MQ, 1-MQ, Type : Synthetic small molecule analog Research Focus : Weight Loss, Mitochondrial Function, Longevity, Metabolic Health Scientific References Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Animal Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes mellitus Review What is 5-Amino-1MQ
Quick and Convenient Visits Perfect for busy schedules
US$ 28.89
US$ 27.42
US$ 25.15
US$ 29.22
US$ 27.46
